EGFRwt
Showing 1 - 5 of 5
Malignant Glioma, Brain Tumor, Recurrent Trial in Durham (D2C7-IT)
Active, not recruiting
- Malignant Glioma
- Brain Tumor, Recurrent
-
Durham, North CarolinaPreston Robert Tisch Brain Tumor Center at Duke
Jul 12, 2022
Non Small Cell Lung Cancer Trial in Guangzhou (SI-B001, AP or TP, Docetaxel)
Recruiting
- Non Small Cell Lung Cancer
- SI-B001
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center (SYSUCC)
Mar 14, 2022
Lung Tumor Trial in São Paulo (Alectinib, Pembrolizumab, Nivolumab)
Active, not recruiting
- Lung Neoplasm
- Alectinib
- +3 more
-
São Paulo, BrazilHospital Municipal Vila Santa Catarina
Oct 5, 2021
Malignant Glioma Trial in Durham (D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three
Recruiting
- Malignant Glioma
- D2C7-IT (6920 ng/mL via convection-enhanced delivery)
- +2 more
-
Durham, North CarolinaDuke University Medical Center
Mar 22, 2022
NSCLC Trial in Worldwide (Capmatinib, Spartalizumab, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Capmatinib
- +2 more
-
Fayetteville, Arkansas
- +7 more
Jan 21, 2022